Discovery of molecular glue degraders for substance use disorder targets and pathways

Active Grant Awarded

Award ID
RDA067921UJFL45
Recipient
Awarding agency
Obligated
$252,750

Award facts

Completion date 1% complete
Place of performance
Cambridge, MA 02138, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through the National Institute on Drug Abuse, awarded $252,750 to President and Fellows of Harvard College on November 16, 2026, under Grant RDA067921UJFL45 and Assistance Listing 93.DA1, Drug Use and Addiction Research Programs - Research Projects. The project investigates molecular glue degraders for substance use disorder targets and pathways. Its project summary identifies aberrant activation of the activator protein 1 (AP-1) transcription pathway, driven by accumulation of the transcription factor dFosB, as a central pathway underlying addiction. The summary describes a chemically distinct molecular glue degrader library, built on privileged ligands and a screening platform, that recruits target proteins to the E3 ligase cereblon (CRBN) for degradation. The applicant reports that this library has yielded first-in-class compounds capable of degrading therapeutically stubborn proteins, including transcription-factor-like targets in the AP-1 pathway. The period of performance ends November 30, 2028. Place of performance is Cambridge, Massachusetts 02138. The program supports basic, clinical, translational, and implementation research in substance use, and NIDA selects projects based on scientific and technical merit, feasibility, potential contribution to the national drug use problem, and relevance to NIDA priorities.

Description

Abstract
Addiction and substance use disorders (SUD) are debilitating conditions characterized by persistent physiological and behavioral adaptations in the brain's reward circuitry. Remediation of the pathways that drive SUD has the potential to treat many addiction-related disorders. Aberrant activation of the activator protein 1 (AP-1) transcriptional pathway through pathological accumulation of the transcription factor protein δfosb is one of the central pathways underlying the addicted phenotype. However, the discovery of ligands that modulate the AP-1 pathway is challenging, as these transcription factors lack obvious binding sites for traditional small molecule inhibitors and must be capable of passing the blood-brain barrier. Thus, although modulating the AP- 1 pathway is a clear therapeutic target in SUD, pharmacological means of remediating this pathway remain an unmet need. Targeted protein degradation is a unique therapeutic strategy that uses molecular glue degraders to clear pathogenic proteins. These small molecules act by recruiting target proteins to an E3 ligase like cereblon (CRBN), leading to their ubiquitination and proteasomal degradation. This mechanism of action overcomes traditional barriers in small molecule ligand development for challenging targets like those in the AP-1 pathway (i.e., transcription factors). We have developed a chemically distinct molecular glue degrader library that uses privileged ligands inspired by the natural substrate recognition mechanisms for CRBN and also possesses favorable drug-like properties that suggest compatibility with blood-brain barrier penetration. This library and screening platform has yielded first-in-class compounds capable of degrading therapeutically stubborn proteins, including those that are reminiscent of transcription factors in the AP-1 pathway. As such, investigation of molecular glue degraders for the AP-1 pathway is a differentiated approach that has the potential to provide new probes and opportunities for treatment of SUD. We hypothesize that a targeted protein degradation approach is uniquely suited to potently and selectively clear therapeutic targets in SUD. We will test this hypothesis by thorough examination of our molecular glue degrader library in several reporter assays and subsequent mechanistic characterization of identified hits with collaborators specializing in SUD biology and AP-1 signaling. First, we will develop in vitro and cellular reporter assays for known targets in the AP-1 pathway, like δfosb, and use these assays for high-throughput screening against the molecular glue degrader library. Second, we will develop and screen reporter assays for AP-1 pathway activation for HIT identification, followed by unbiased proteomics experiments for target discovery and validation. These investigations will yield new chemical probes, reporter assays, and screening pipelines for SUD targets and pathways that have the potential to overcome historical challenges in targeting the AP-1 signaling pathway and expedite strategies for the study and treatment of SUD.

Quick answers

Who received award RDA067921UJFL45?

RDA067921UJFL45 was awarded to President And Fellows Of Harvard College by National Institute on Drug Abuse (National Institutes of Health) on November 16, 2026.

How much is award RDA067921UJFL45 worth?

$252,750 has been obligated on RDA067921UJFL45.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award